Skip to main content
Communications Biology logoLink to Communications Biology
. 2020 May 7;3:214. doi: 10.1038/s42003-020-0939-8

Improved designs for pET expression plasmids increase protein production yield in Escherichia coli

Patrick J Shilling 1,, Kiavash Mirzadeh 1,2, Alister J Cumming 1, Magnus Widesheim 1, Zoe Köck 1,3, Daniel O Daley 1,
PMCID: PMC7205610  PMID: 32382055

Abstract

The pET series of expression plasmids are widely used for recombinant protein production in Escherichia coli. The genetic modules controlling transcription and translation in these plasmids were first described in the 1980s and have not changed since. Herein we report design flaws in these genetic modules. We present improved designs and demonstrate that, when incorporated into pET28a, they support increases in protein production. The improved designs are applicable to most of the 103 vectors in the pET series and can be easily implemented.

Subject terms: Synthetic biology, Expression systems


Patrick Shilling et al. increase the protein production yield from the pET28a expression plasmid by modifying the genetic modules that control transcription and translation initiation. These improved designs are applicable to most vectors in the pET series and can be easily implemented.

Introduction

Studier and co-workers1,2 described the first pET expression plasmid more than thirty years ago. They integrated the strong φ10 promoter for the T7 RNA polymerase (T7 promoter) and the Tφ transcription terminator (T7 terminator) into the pBR322 backbone and established the pET nomenclature (plasmid for expression by T7 RNA polymerase). Novagen and Invitrogen subsequently expanded the series to 103 unique expression plasmids. These expression plasmids support high levels of transcription in strains of Escherichia coli that contain a lysogenised DE3 phage fragment encoding the T7 RNA polymerase and they have become a workhorse for the scientific community3,4. To date, they have been described in >220,000 published research studies (>12,000 per year; Supplementary Fig. 1).

pET28a is the most popular expression plasmid on the market (described in >40,000 published articles). It contains the T7 promoter and an adjacent lac operator sequence that is included to suppress uninduced expression5. Translation initiation is mediated by a Shine–Dalgarno (SD) sequence originating from the major capsid protein of T7 (gene 10 protein). In a typical experiment, the coding sequence to be expressed is cloned downstream of, and in frame with, the coding sequence for a poly-histidine purification tag (His6) and a thrombin protease recognition site (TPS) so that the recombinant protein produced can be easily purified using standardised protocols. The salient features of pET28a are presented in Fig. 1a.

Fig. 1. Salient features of pET28a, design flaws and improved designs.

Fig. 1

a Genetic elements present in pET28a include the φ10 (T7) promoter and the lac operator, as well as the translation initiation region (TIR) encompassing the Shine–Dalgarno (SD) sequence, a spacer and the first five codons of the coding sequence. b The φ10 (T7) promoter in pET28a is a truncated variant of the consensus φ10 (T7) promoter (T7pCONS). c Inclusion of the T7pCONS results in a three-fold increase in sfGFP levels. Data are presented as mean ± s.d. (n = 3). A statistically significant difference of p < 0.001 relative to pET28a (two-tailed Student’s t test) is denoted by ***.

In this study, we have identified design flaws in the pET series of expression plasmids, which limit protein production yields. We noted that (1) the T7 promoter consensus sequence was truncated in the T7lac promoter, and (2) that the translation initiation region (TIR) may have originally been formed by ad hoc genetic fusion. We describe solutions that rectify these design flaws, and demonstrate that when incorporated into pET28a, they increase protein production for three different proteins. The study therefore describes an easily implementable strategy for increasing recombinant protein yields using pET expression plasmids.

Results

The T7lac promoter lacks the complete T7 consensus sequence

The first design flaw in pET28a is in the T7 promoter. The nucleotide sequence is derived from the consensus φ10 promoter in the T7 phage, which is 23 nucleotides long and sits −17 to +6 relative to the messenger RNA (mRNA) start site (Fig. 1b)6. We noted that pET28a only contains the −17 to +2 region, as four nucleotides were removed when the lac operator sequence was originally introduced in the early generation pET plasmids (designated T7lac)5. At the time it was stated that the lac operator has little effect on induced protein expression levels. Subsequent work suggested that divergence from the consensus T7 promoter (designated T7pCONS) sequence decreases productive transcription initiation7. To determine if the +3 to +6 nucleotides are important in the context of pET28a, we compared the expression levels of the superfolder green fluorescent protein (His6-TPS-sfGFP, hereafter referred to as sfGFP) from the commercially available pET28a and a variant where we had engineered in the T7pCONS. We noted a three-fold increase in production yields of sfGFP in BL21(DE3) pLysS when T7pCONS was used (Fig. 1c). Similar results were observed when using alternative strains such as C41 and C438 (Supplementary Fig. 2a, b) and when T7pCONS was engineered into pET15b, which also includes the same T7lac promoter as pET28a (Supplementary Fig. 3a–c). The restoration of the T7 promoter to T7pCONS did not change the sequence of the lac operator or its proximity from the coding sequence, and we still observed repression prior to induction (Supplementary Fig. 4). The experiment indicates that T7pCONS is more efficient than the truncated variant (−17 to +2) that is currently used in pET28a. The truncation of the T7 promoter is therefore a design flaw that reduces protein production. This design flaw is present in all pET expression plasmids containing T7lac (i.e. 88 of the 103 plasmids; Supplementary Fig. 1). In the remaining pET plasmids, the lac operator was not fused and the T7pCONS is intact.

Translation initiation is affected by ad hoc plasmid assembly

The second design flaw in pET28a is in the TIR. The TIR is a stretch of ~30 nucleotides that is recognised by the 30S ribosomal subunit during translation initiation911. In a native E. coli mRNA, the TIR contains the SD sequence, a spacer that is between five and nine nucleotides in length12,13, and the first five codons of the coding sequence (i.e. the first ribosomal footprint)14,15. Recent literature has indicated that native TIRs have co-evolved with the E. coli ribosomes and are less likely to be sequestered into local mRNA structures compared to the rest of the coding sequence16,17. The lack of mRNA structure is thought to promote the accessibility of the 30S subunit during translation initiation1821. In pET28a the TIR is a composite of the SD sequence and a seven-nucleotide long spacer region from the major capsid protein of T7, and the first five codons of the plasmid encoded open reading frame (MGSSH). This region was constructed by Novagen and there is no publicly available literature describing its construction. We assume that it was assembled by ad hoc fusion of genetic modules rather than considering co-evolution with E. coli ribosomes. We therefore implemented a synthetic evolution approach to identify a TIR that was presumably more compatible with host cell ribosomes22,23. In the experiment, we used the standard pET28a as a template to generate two TIR libraries: one library covered >30,000 TIR variants and a second library that covered >16M possible TIR variants. We then tested the ability of TIR variants to support production of sfGFP by using a translational coupling device and β-lactamase24 (Fig. 2). Initially, the TIR libraries were limited to synonymous codon changes at positions +2, +3 and we identified a TIR (TIR-1) that increased the production of sfGFP in BL21(DE3) pLysS by up to 13-fold (Fig. 3a, b). In a second experiment, we allowed all possible changes in codons +2, +3 and identified a TIR (TIR-2) that increased the production of sfGFP in BL21(DE3) pLysS by up to 47-fold (Fig. 3a, b). It is unlikely that TIR-2 altered protein stability, as the original N-terminal amino acids (MG−) and the substituted amino acids (MQ−) are both considered stable according to the N-end rule25. Similar increases in production were observed when TIR-2 was used in the C41 and C43 strains (Supplementary Fig. 2c, d). In contrast to the synthetic evolution approach, attempts to identify optimal TIRs using bioinformatic algorithms were not successful (Supplementary Figs. 5 and 6). Taken together, these experiments indicate that the TIR in pET28a is not optimal for the production of sfGFP. The TIRs we identified are more effective in protein production experiments, and are directly applicable to pET14b, pET15b and pET28b–c, which possess the same TIR (Supplementary Fig. 7). Moreover, the synthetic evolution approach is applicable to all pET expression plasmids, as none, to our knowledge, have a TIR that has evolved with the host cell ribosomes.

Fig. 2. Method for synthetic evolution of the translation initiation region (TIR).

Fig. 2

a Schematic of the pET28a-His6-TPS-sfGFP-translational coupling device-β-lactamase expression cassette. The plasmid encodes for a His6-tag, a thrombin protease site (TPS), sfGFP (green arrow), followed by a translational coupling device (hp; weak coupling 1) and the reporter, β-lactamase (bla; purple arrow). The boxed area represents the TIR for the expression cassette. b The pET28a-His6-sfGFP-hp-bla plasmid was used as a template for the creation of TIRLIBRARIES; degenerate primers used to create a TIRLIBRARY with synonymous codon changes and one with non-synonymous codon changes. c Following preparation of a TIRLIBRARY plasmids were transformed into E. coli BL21(DE3) pLysS. TIRLIBRARY variants that showed higher levels of protein expression are able to grow on plates at higher concentrations of ampicillin relative to the standard pET28a and were selected.

Fig. 3. Synthetically evolved TIRs promote increased sfGFP production levels.

Fig. 3

a Synthetic evolution of the pET28a-TIR resulted in two sequence variants (TIR-1 and TIR-2). Altered nucleotides for the TIR variants are shown in green text. b Inclusion of TIR-1 and TIR-2 resulted in up to a 13- and 47-fold increase in sfGFP production levels, respectively. Data are presented as mean ± s.d. (n = 3). A statistically significant difference of p < 0.001 relative to pET28a (two-tailed Student’s t test) is denoted by ***.

Implementation of design solutions in pET28a

We created an improved version of the pET28a expression plasmid by engineering combinations of the T7pCONS together with either TIR-1 or TIR-2 (Fig. 4a). When combined we observed a 33- to 121-fold increase, respectively, in the synthesis of sfGFP compared to the standard version of pET28a (Fig. 4b). We also asked whether the improved version of the pET28a expression plasmid could increase protein production for alternative proteins. We tested the production yields for two human proteins, the putative cancer target MTH126,27 and the DNA glycosylase Neil3. We observed a greater than two-fold increase in protein production when we engineered T7pCONS together with TIR-2 for both His6-TPS-MTH1 and His6-TPS-Neil3 (referred to as MTH1 and Neil3, respectively) (Fig. 4c, d). Varying results were observed however when either T7pCONS or TIR-2 were used individually, revealing interesting context-specific expression profiles. The addition of T7pCONS resulted in a marginal increase in overall production for MTH1 compared to the standard pET28a (Fig. 4c), whereas Neil3 showed a greater than three-fold increase (Fig. 4d). Engineering TIR-2 alone lead to two-fold increases for both MTH1 and Neil3 over the standard pET28a (Fig. 4c, d). Despite sharing identical promoters and TIRs, these results highlight the somewhat unpredictable nature of recombinant protein production.

Fig. 4. Combining the T7pCONS and TIR variants increases production efficiency.

Fig. 4

a Schematic of the pET28a transcription and translation initiation region. In a standard production experiment, the coding sequence for the protein of interest is inserted in frame with the His6-tag and thrombin protease site (His6-TPS). b Engineering the T7pCONS in combination with either TIR-1 or TIR-2 resulted in an improvement in protein production. For sfGFP a maximal 121-fold increase was observable relative to the standard pET28a (left panel). sfGFP is the major protein constituent when T7pCONS and TIR-2 are combined (right panel). c, d. MTH1 and Neil3 production is enhanced by the addition of the combined TIR-2 and T7pCONS. Data are presented as mean ± s.d. (n = 3). A statistically significant difference of p < 0.05, p < 0.01 or p < 0.001 relative to pET28a (two-tailed Student’s t test) is denoted by *, ** and ***, respectively.

Do increased production yields affect the solubility of the recombinant protein? We harvested cells expressing either sfGFP, MTH1 or Neil3 following induction from the commercially available pET28a expression plasmid, and then lysed and fractionated the cellular components into soluble and insoluble fractions. We observed that sfGFP and MTH1 were largely soluble, while Neil3 was largely insoluble (Fig. 5). We then repeated the experiment using the improved version of the pET28a expression plasmid, which contained T7pCONS together with TIR-2. We again observed that sfGFP and MTH1 remained largely soluble, while Neil3 remained largely insoluble (Fig. 5). Consequently, the increased production yields obtained by incorporating more effective genetic modules into pET28a did not impact on overall protein solubility in the cell.

Fig. 5. Cellular fractionation following expression from standard pET28a plasmid versus TIR-2 + T7pCONS plasmid.

Fig. 5

Western blot quantification of fractionations of BL21(DE3) pLysS (total, soluble and insoluble) following expression of a sfGFP, b MTH1 or c Neil3 from either the standard pET28a plasmid (pink bars) or pET28a-TIR-2+T7pCONS plasmid (green bars). In all examples, application of the combined TIR-2+T7pCONS resulted in enhanced levels of target proteins. Furthermore, use of TIR-2+T7pCONS did not alter the solubility profile for each target. Representative Western blots are shown on the right panels with each protein marked. Data are presented as mean ± s.d. (n = 3).

Conclusions

Although the pET plasmid series work off the shelf, we have demonstrated that they contain design flaws in the genetic modules controlling transcription and translation initiation. We have identified improved designs that include (1) a restoration of the conserved T7 promoter (T7pCONS) and (2) synthetically evolved TIRs (TIR-1, -2). These improved designs work in combination to increase protein production yields in pET28a. They are easily incorporated and applicable across the majority of pET expression plasmids.

Methods

Google Scholar database searches

Individual plasmid names from the pET (Novagen), pET (Invitrogen), pGEX (GE Healthcare), pQE (Qiagen) and pBAD (Invitrogen) plasmid series were queried in Google Scholar to determine the number of times each was used in a publication. For pET plasmids with multiple letter suffixes, the suffix would be included; for instance, pET28a, pET28b, pET28c and so on. The average number of times the pET series as a whole were used in publications per year was measured using a 5-year time span from 2014 to 2018. Searches included both publication in scientific journals and patents.

Molecular cloning

All polymerase chain reactions (PCR) were carried out with the Q5-polymerase (New England Biolabs, USA). Oligonucleotide synthesis and DNA sequencing was performed by Eurofins Scientific (Eurofins genomics, Germany). Oligonucleotides used for this study are found in Supplementary Table 1. Cloning of the coding sequence for sfGFP into pET28a was performed by standard restriction enzyme digestion and T4 ligation (New England Biolabs, USA) using the NdeI and XhoI sites, preserving the 5′ His6 and thrombin protease recognition coding sequence. The coding sequence for sfGFP was PCR amplified, incorporating the 5′ NdeI and 3′ XhoI restriction recognition sites as primer extensions. Generation of the pET28a-His6-TPS-sfGFP-translational coupling device (hp)-β-lactamase (bla) plasmid was carried out using the Gibson cloning method28. In brief, PCR products were generated for the pET28a-His6-TPS-sfGFP (described above) and β-lactamase, sourced from the pETDUET-1 template (Novagen, Germany). A translational coupling device (weak coupling 1)24 was incorporated during the Gibson cloning step, via a 30-bp complementary overlapped region between the 3′ end of the pET28a-His6-TPS-sfGFP PCR product, and the 5′ end of the β-lactamase PCR product. All coding sequences are shown in Supplementary Figs 811. Human Neil3 (kindly provided by Pål Stenmark) was inserted into pET28a between the NdeI and XhoI restriction sites via Gibson assembly. All primer sequences are shown in Supplementary Table 1.

Mutagenesis of pET28a φ10 promoter

Mutagenesis of the φ10 promoter was carried out using the method of Liu and Naismith29. Briefly, the region encompassing the φ10-promoter initiator region (+2 to +6, GAGA) was incorporated into the 13 bp overlap of both the forward and reverse primer. The primers had sufficient complementarity to the template such that complementation to the template was favoured over primer dimer formation. Primer sequences are shown in Supplementary Table 1.

sfGFP fluorescence assays

Fluorescence assays were carried out as described30 with minor modifications. Clones were transformed into chemically competent BL21(DE3) pLysS, C41 or C43. Three biological replicates were grown overnight at 37 °C with shaking at 180 RPM in 1 mL Luria–Bertani (LB) plus antibiotics in 96-well 2 mL deep-well culture plates. Overnight cultures were used to inoculate 5 mL LB plus antibiotics in a 24-well growth plate and incubated at 37 °C with shaking at 180 RPM until an OD600 of 0.5 was reached. Expression was induced by the addition of 1 mM isopropyl-β-D thiogalactopyranoside (IPTG) and cultures were incubated for 2 h at 37 °C with shaking at 180 RPM. The OD600 was measured, followed by collection of 1 mL of culture by centrifugation at 3220 × g for 15 min. The media were removed and pelleted cells were resuspended in 200 μL buffer (50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 15 mM EDTA), and transferred to a 96-well optical bottom black-wall plate (Thermo Scientific). Following a 2-h incubation at room temperature, which enabled sfGFP to mature, fluorescence was read in a Spectramax Gemini (Molecular Devices) at an excitation and emission wavelength of 485 and 510 nm, respectively. Calculations of sfGFP yield per litre were determined based on a calibration curve, using purified sfGFP of known concentration. Quantification data are available in Supplementary Data 1 file (excel format).

Generation of TIR libraries

TIR libraries (TIRLIBRARIES) were generated by amplifying either the pET28a-sfGFP-hp-bla expression plasmid by PCR, using overlapping primers as previously described22,31. For each library, the forward primer incorporated six degenerate nucleotides before the initiating start codon, and either synonymous or non-synonymous codon changes for the +2 and +3 codons (Gly, Ser). The reverse primer overlapped with the forward primer by 14 nucleotides, thus allowing circularisation of the PCR product by homologous recombination in the E. coli strain MC1061. The PCR was carried out using a programme that consisted of a denaturation step at 94 °C for 5 min, followed by 30 cycles of 95 °C for 45 s, 40–70 °C for 45 s (using a gradient thermocycler), 72 °C for 4 min and a final elongation step of 72 °C for 5 min. PCR products that were successfully amplified at the lowest annealing temperature with no contaminating non-specific PCR fragments were used for subsequent steps. Twenty-five microlitres of the PCR reaction was treated with DpnI, followed by transformation into 200 μL chemically competent E. coli MC1061 using standard protocols that included a 2-min heat shock at 42 °C and a 60-min recovery at 37 °C. The transformation was transferred into 4 × 5 mL LB media containing 50 μg/mL kanamycin contained in 4 × 50 mL conical tubes, and incubated overnight at 37 °C with shaking at 180 RPM. Isolation of the TIRLIBRARIES was carried out using four E.Z.N.A DNA mini kit purification columns (Omega Bio-tek, USA) according to the manufacturer’s instruction, followed by pooling of the eluates. All primer sequences for the generation of TIRLIBRARIES are shown in Supplementary Table 1.

Screening of TIR libraries

TIRLIBRARIES were screened by transforming chemically competent BL21(DE3) pLysS using standard protocols and comparing colony formation on plates containing increasing amounts of ampicillin. Specifically, 500 ng of the TIRLIBRARY was transformed into 50 μL of chemically competent BL21(DE3) pLysS using standard protocols. Following recovery, the whole transformation mixture was seeded into 3 mL of LB contained in a 15 mL conical tube, followed by incubation at 37 °C with shaking at 180 RPM for 16 h. The overnight culture was used to inoculate (1:50) 5 mL of fresh LB containing 50 μg/mL kanamycin and 34 μg/mL chloramphenicol. Cultures were grown until reaching an OD600 of 0.3, whereupon expression of the coding sequence was induced by plating a volume of cells corresponding to 0.01 OD600 units onto LB-agar plates (45 mm diameter) containing 0.25 mM IPTG, and increasing concentrations of ampicillin (100–4000 μg/mL). In order to ensure selection of optimal clones, based only on β-lactamase production, we selected clones only using ampicillin. Kanamycin and chloramphenicol, which are used to maintain pET28a and pLysS respectively, were omitted from the LB-agar plates. We reasoned that the use of kanamycin and chloramphenicol would apply too great a selection pressure on developing colonies. While not necessarily an important step, we have noted it so that readers can replicate our experiments. The plates were then incubated for ~120 h at 20 °C. A TIRLIBRARY was deemed successful if colonies were capable of withstanding concentrations of ampicillin higher than colonies harbouring a plasmid with the standard TIR. For plates where TIRLIBRARY variants showed greater resistance to ampicillin compared to a standard TIR, ten colonies were selected for further analysis and sequencing (Eurofins MWG operon, Germany). Determination of sfGFP production was carried out in triplicate by the previously described fluorescence assay. Determination of MTH1 production levels was performed by Western blotting. For both protein targets, the best five clones exhibiting high levels of protein production were carried onto the next stage of evaluation. To exclude the possibility that mutations away from the TIR promoted higher expression levels, the best five selected expression variant TIR sequences were back-engineered into the original pET28a-His6-TPS-sfGFP-hp-bla and pET28a-His6-TPS-sfGFP expression vectors, and sfGFP assay or Western blot performed, respectively. The best TIR variant was then chosen for subsequent testing. The primer sequences for generating TIR-1 or TIR-2 (sfGFP) are shown in Supplementary Table 1.

Protein expression and fractionation

Overnight cultures (100 mL LB supplemented with 50 μg/mL kanamycin and 34 μg/mL chloramphenicol) were inoculated from freshly transformed BL21(DE3) pLysS expressing sfGFP, MTH1 or Neil3 in either the standard pET28a or pET28a-TIR-2+T7pCONS plasmid. Overnight cultures were grown at 37 °C with shaking at 200 RPM. The following morning, the overnight culture was used to inoculate 500 mL LB supplemented with 50 μg/mL kanamycin and 34 μg/mL chloramphenicol, to a starting OD = 0.05. Cultures were grown at 37 °C with shaking at 200 RPM until reaching an OD600 = 0.5–0.7. Specifically, for sfGFP and Neil3, induction was induced immediately with 1 mM IPTG and allowed to incubate at 37 °C with shaking at 200 RPM for 2 h. For MTH1, the medium was cooled by incubation at 4 °C for 10 min, followed by induction with 1 mM IPTG and subsequent incubation at 16 °C with shaking at 200 RPM, overnight for 20 h. Following the allotted induction time, cells were harvested at 4000 × g for 20 min at 4 °C. Bacterial pellets were resuspended in 50 mL standard buffer (20 mM Tris (pH 7.0), 150 mM NaCl). Cell pellet resuspensions were made homogeneous with a glass Dounce homogeniser. Resuspended cells were lysed by three passes at 10,000–15,000 PSI in an Avestin emulsiflex C3 high-pressure homogeniser (Avestin, Canada). Following collection of a total lysate sample, lysed cells were then centrifuged at 22,000 × g for 1 h. The supernatant (soluble fraction) was collected by gentle aspiration and pellet fractions (insoluble fraction) resuspended in an equivalent volume of standard buffer. Samples were collected and run on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel followed by Western blotting. All constructs and conditions were carried out in triplicate.

SDS-PAGE and Western blotting

SDS-PAGE was carried out on a 4–12% Bis-tris Midi Protein Gel in an XCell4 SureLock Midi system (Invitrogen, USA) or 12% Bis-tris acrylamide using a Hoefer Mighty Small II Mini Vertical Electrophoresis System with a 1 mm thickness. The running buffer used was premixed with NuPAGE MES SDS (Invitrogen, USA). Samples consisted of whole-cell lysates or fractionated cells (total, soluble, insoluble), and were prepared first by incubation at 95 °C for 10 min, or 65 °C for sfGFP to preserve the folded fluorescent form used for in-gel fluorescence. For normalised consistent loading, the equivalent of 0.1 or 0.05 OD600 units were applied to each well. Western blotting was carried out on PVDF or nitrocellulose membranes using either an XCell-II or an iBlot Module (Invitrogen, USA), respectively.

For PVDF membranes probed against the His6 epitope: Gels transferred to PVDF were incubated in transfer buffer (Towbin buffer: 25 mM Tris, 192 mM glycine, 20% (v/v) methanol) for 15 min, followed by transfer to PVDF for 1 h at 30 V. Membranes were incubated in 5% skim milk powder (PanReac AppliChem) in TBS (50 mM Tris, pH 7.4, 200 mM NaCl) for 1 h at room temperature. Membranes were decorated with HisProbe-HRP conjugate (Thermo Scientific, USA) at 1:10,000. Membranes were developed with SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Scientific, USA) on an Azure c600 Western Blot Imaging System (Azure Biosystems, USA). For nitrocellulose membranes probed against MTH1: Proteins were transferred to nitrocellulose for 7 min at 20 V using an iBlot Module. Membranes were incubated in 5% skim milk powder (Bio-Rad, USA) for 1 h at room temperature. Membranes were decorated with primary mouse anti-MTH1 antibody (MABC1040, Millipore) at 1:1000 dilution for 1 h at room temperature, followed by decoration with secondary donkey anti-mouse IR-680 antibody at 1:10,000 (LI-COR, USA). Nitrocellulose membranes were developed on an Odyssey Imaging System (LI-COR, USA). Western blots were analysed by Image J. Original uncropped gels and blots are presented in Supplementary Figs. 1217. Quantification data are available in Supplementary Data 1 file (excel format).

In silico TIR predictions

Three prediction algorithms were used for the creation of in silico TIRs (RBS calculator32, UTR designer33 and RBS designer34). For RBS calculator, version 2.1 was tested. Presets included: pre-sequence position: −70 to −30; coding sequence from position 1 until +60; goal: maximise; organism: E. coli BL21(DE3) (ACCTCCTTA). UTR designer: constraints for 5′-UTR: 25 × N; coding sequence: position 1 until +60; desired protein level: maximal; organism: E. coli (ACCUCCUUA); with no optimisation of codon content. RBS designer: 5′-UTR: position −70 until −24; optimise upstream length: ten nucleotides (default); SD: AAGGAA (default); optimise spacer length: seven nucleotides; coding sequence: position +1 until +60; organism: E. coli; target efficiency: 1.0. The best three variant sequences for each programme were utilised for the creation of in silico predicted TIRS in pET28a-sfGFP. Mutagenesis primers were designed and incorporated into pET28a-sfGFP using the previously described mutagenesis methodology. All primer sequences for generation of in silico predicted TIRS are shown in Supplementary Table 1.

Statistics and reproducibility

All experiments where statistical calculations were applied used three biological replicates. All data are presented as the mean ± the standard deviation. Statistical analysis was performed by the Student’s t test. P values considered statistically significant are indicated by asterisk symbols within the figure legends.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

42003_2020_939_MOESM2_ESM.pdf (33.5KB, pdf)

Description of Additional Supplementary Files

Supplementary Data 1 (65.1KB, xlsx)
Reporting Summary (81.7KB, pdf)
Peer Review File (109.5KB, pdf)

Acknowledgements

We thank Pål Stenmark for the pET28a-His6-TPS-MTH1 and pET28a-Neil3 constructs and Jan-Willem de Gier for the C41 and C43 strains. D.O.D. was supported by a grant from the Swedish Research Council and the Carl Trygger stiftelse. Open access funding provided by Stockholm University.

Author contributions

P.J.S., K.M., M.W. and D.O.D. designed the study. P.J.S., K.M., A.J.M. and Z.K. carried out the experiments. P.J.S. and D.O.D. wrote the paper.

Data availability

All relevant data are available from the corresponding authors upon request. Source data underlying plots shown in figures are presented in Supplementary Data 1. Full blots are shown in Supplementary Information.

Competing interests

The synthetic evolution process used in the study is patent protected (PCT/SE2015/051343; European Patent no. 3234146). The patent is the property of CloneOpt AB, of which K.M. and D.O.D. are shareholders. All the other authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Patrick J. Shilling, Email: patrick.shilling@dbb.su.se

Daniel O. Daley, Email: ddaley@dbb.su.se

Supplementary information

Supplementary information is available for this paper at 10.1038/s42003-020-0939-8.

References

  • 1.Rosenberg AH, et al. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene. 1987;56:125–135. doi: 10.1016/0378-1119(87)90165-X. [DOI] [PubMed] [Google Scholar]
  • 2.William Studier, F., Rosenberg, A. H., Dunn, J. J. & Dubendorff, J. W. in Methods in Enzymology, Vol. 185, 60–89 (Elsevier, 1990). [DOI] [PubMed]
  • 3.Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front. Microbiol. 2014;5:172. doi: 10.3389/fmicb.2014.00172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Rosano GL, Morales ES, Ceccarelli EA. New tools for recombinant protein production in Escherichia coli: a 5‐year update. Protein Sci. 2019;28:1412–1422. doi: 10.1002/pro.3668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Dubendorff JW, Studier FW. Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor. J. Mol. Biol. 1991;219:45–59. doi: 10.1016/0022-2836(91)90856-2. [DOI] [PubMed] [Google Scholar]
  • 6.Dunn JJ, Studier FW, Gottesman M. Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J. Mol. Biol. 1983;166:477–535. doi: 10.1016/S0022-2836(83)80282-4. [DOI] [PubMed] [Google Scholar]
  • 7.Lopez PJ, Guillerez J, Sousa R, Dreyfus M. The low processivity of T7 RNA polymerase over the initially transcribed sequence can limit productive initiation in vivo. J. Mol. Biol. 1997;269:41–51. doi: 10.1006/jmbi.1997.1039. [DOI] [PubMed] [Google Scholar]
  • 8.Miroux B, Walker JE. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 1996;260:289–298. doi: 10.1006/jmbi.1996.0399. [DOI] [PubMed] [Google Scholar]
  • 9.Laursen BS, Sørensen HP, Mortensen KK, Sperling-Petersen HU. Initiation of protein synthesis in bacteria. Microbiol. Mol. Biol. Rev. 2005;69:101–123. doi: 10.1128/MMBR.69.1.101-123.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Milón P, Rodnina MV. Kinetic control of translation initiation in bacteria. Crit. Rev. Biochem. Mol. Biol. 2012;47:334–348. doi: 10.3109/10409238.2012.678284. [DOI] [PubMed] [Google Scholar]
  • 11.McCarthy JE, Gualerzi C. Translational control of prokaryotic gene expression. Trends Genet. 1990;6:78–85. doi: 10.1016/0168-9525(90)90098-Q. [DOI] [PubMed] [Google Scholar]
  • 12.Osterman IA, Evfratov SA, Sergiev PV, Dontsova OA. Comparison of mRNA features affecting translation initiation and reinitiation. Nucleic Acids Res. 2013;41:474–486. doi: 10.1093/nar/gks989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chen H, Bjerknes M, Kumar R, Jay E. Determination of the optimal aligned spacing between the Shine–Dalgarno sequence and the translation initiation codon of Escherichia coli mRNAs. Nucleic Acids Res. 1994;22:4953–4957. doi: 10.1093/nar/22.23.4953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ingolia NT, Ghaemmaghami S, Newman JRS, Weissman JS. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science. 2009;324:218–223. doi: 10.1126/science.1168978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Reeve B, Hargest T, Gilbert C, Ellis T. Predicting translation initiation rates for designing synthetic biology. Front. Bioeng. Biotechnol. 2014;2:1. doi: 10.3389/fbioe.2014.00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mortimer SA, Kidwell MA, Doudna JA. Insights into RNA structure and function from genome-wide studies. Nat. Rev. Genet. 2014;15:469–479. doi: 10.1038/nrg3681. [DOI] [PubMed] [Google Scholar]
  • 17.Scharff LB, Childs L, Walther D, Bock R. Local absence of secondary structure permits translation of mRNAs that lack ribosome-binding sites. PLoS Genet. 2011;7:e1002155. doi: 10.1371/journal.pgen.1002155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kudla G, Murray AW, Tollervey D, Plotkin JB. Coding-sequence determinants of gene expression in Escherichia coli. Science. 2009;324:255–258. doi: 10.1126/science.1170160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Plotkin JB, Kudla G. Synonymous but not the same: the causes and consequences of codon bias. Nat. Rev. Genet. 2011;12:32–42. doi: 10.1038/nrg2899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Goodman DB, Church GM, Kosuri S. Causes and effects of N-terminal codon bias in bacterial genes. Science. 2013;342:475–479. doi: 10.1126/science.1241934. [DOI] [PubMed] [Google Scholar]
  • 21.Bentele K, Saffert P, Rauscher R, Ignatova Z, Blüthgen N. Efficient translation initiation dictates codon usage at gene start. Mol. Syst. Biol. 2013;9:675. doi: 10.1038/msb.2013.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mirzadeh K, et al. Enhanced protein production in Escherichia coli by optimization of cloning scars at the vector-coding sequence junction. ACS Synth. Biol. 2015;4:959–965. doi: 10.1021/acssynbio.5b00033. [DOI] [PubMed] [Google Scholar]
  • 23.Daley, D., Mirzadeh, K., Toddo, S. & Guntur, S. Selective Optimisation of a Ribosome Binding Site for Protein Productionhttps://www.google.com/patents/WO2016099388A1?cl=da (2015). Accessed 16 Mar 2018.
  • 24.Rennig M, et al. TARSyn: tunable antibiotic resistance devices enabling bacterial synthetic evolution and protein production. ACS Synth. Biol. 2018;7:432–442. doi: 10.1021/acssynbio.7b00200. [DOI] [PubMed] [Google Scholar]
  • 25.Tobias J, Shrader T, Rocap G, Varshavsky A. The N-end rule in bacteria. Science. 1991;254:1374–1377. doi: 10.1126/science.1962196. [DOI] [PubMed] [Google Scholar]
  • 26.Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014;508:215–221. doi: 10.1038/nature13181. [DOI] [PubMed] [Google Scholar]
  • 27.Huber KVM, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508:222–227. doi: 10.1038/nature13194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gibson DG, et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods. 2009;6:343–345. doi: 10.1038/nmeth.1318. [DOI] [PubMed] [Google Scholar]
  • 29.Liu H, Naismith JH. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol. 2008;8:91. doi: 10.1186/1472-6750-8-91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Daley DO, et al. Global topology analysis of the Escherichia coli inner membrane proteome. Science. 2005;308:1321–1323. doi: 10.1126/science.1109730. [DOI] [PubMed] [Google Scholar]
  • 31.Mirzadeh K, Toddo S, Nørholm MHH, Daley DO. Codon optimizing for increased membrane protein production: a minimalist approach. Methods Mol. Biol. (Clifton, NJ) 2016;1432:53–61. doi: 10.1007/978-1-4939-3637-3_4. [DOI] [PubMed] [Google Scholar]
  • 32.Salis HM, Mirsky EA, Voigt CA. Automated design of synthetic ribosome binding sites to control protein expression. Nat. Biotechnol. 2009;27:946–950. doi: 10.1038/nbt.1568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Seo SW, et al. Predictive design of mRNA translation initiation region to control prokaryotic translation efficiency. Metab. Eng. 2013;15:67–74. doi: 10.1016/j.ymben.2012.10.006. [DOI] [PubMed] [Google Scholar]
  • 34.Na D, Lee D. RBSDesigner: software for designing synthetic ribosome binding sites that yields a desired level of protein expression. Bioinformatics (Oxf., Engl.) 2010;26:2633–2634. doi: 10.1093/bioinformatics/btq458. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

42003_2020_939_MOESM2_ESM.pdf (33.5KB, pdf)

Description of Additional Supplementary Files

Supplementary Data 1 (65.1KB, xlsx)
Reporting Summary (81.7KB, pdf)
Peer Review File (109.5KB, pdf)

Data Availability Statement

All relevant data are available from the corresponding authors upon request. Source data underlying plots shown in figures are presented in Supplementary Data 1. Full blots are shown in Supplementary Information.


Articles from Communications Biology are provided here courtesy of Nature Publishing Group

RESOURCES